scholarly journals Hearing loss in patients on treatment for drug-resistant tuberculosis

2012 ◽  
Vol 40 (5) ◽  
pp. 1277-1286 ◽  
Author(s):  
James A. Seddon ◽  
Peter Godfrey-Faussett ◽  
Kayleen Jacobs ◽  
Adam Ebrahim ◽  
Anneke C. Hesseling ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis

scholarly journals Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model

2019 ◽  
Vol 70 (5) ◽  
pp. 917-924 ◽  
Author(s):  
Hyejeong Hong ◽  
David W Dowdy ◽  
Kelly E Dooley ◽  
Howard W Francis ◽  
Chakra Budhathoki ◽  
...  
Keyword(s):  
South Africa ◽  
Hearing Loss ◽  
Prediction Model ◽  
Predictive Value ◽  
Characteristic Curve ◽  
Hearing Threshold ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Tb Treatment ◽  
Resistant Tuberculosis

Abstract Background Individuals treated for drug-resistant tuberculosis (DR-TB) with aminoglycosides (AGs) in resource-limited settings often experience permanent hearing loss, yet there is no practical method to identify those at higher risk. We sought to develop a clinical prediction model of AG-induced hearing loss among patients initiating DR-TB treatment in South Africa. Methods Using nested, prospective data from a cohort of 379 South African adults being treated for confirmed DR-TB with AG-based regimens we developed the prediction model using multiple logistic regression. Predictors were collected from clinical, audiological, and laboratory evaluations conducted at the initiation of DR-TB treatment. The outcome of AG-induced hearing loss was identified from audiometric and clinical evaluation by a worsened hearing threshold compared with baseline during the 6-month intensive phase. Results Sixty-three percent of participants (n = 238) developed any level of hearing loss. The model predicting hearing loss at frequencies from 250 to 8000 Hz included weekly AG dose, human immunodeficiency virus status with CD4 count, age, serum albumin, body mass index, and pre-existing hearing loss. This model demonstrated reasonable discrimination (area under the receiver operating characteristic curve [AUC] = 0.71) and calibration (χ2[8] = 6.10, P = .636). Using a cutoff of 80% predicted probability of hearing loss, the positive predictive value of this model was 83% and negative predictive value was 40%. Model discrimination was similar for ultrahigh-frequency hearing loss (frequencies >9000 Hz; AUC = 0.81) but weaker for clinically determined hearing loss (AUC = 0.60). Conclusions This model may identify patients with DR-TB who are at highest risk of developing AG-induced ototoxicity and may help prioritize patients for AG-sparing regimens in clinical settings where access is limited.

scholarly journals Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis

2019 ◽  
Vol 59 (3) ◽  
pp. 219-223
Author(s):  
Nazanin Ghafari ◽  
Richard Court ◽  
Maxwell Tawanda Chirehwa ◽  
Lubbe Wiesner ◽  
Lucretia Petersen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hearing Loss ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Multi Drug Resistant Tuberculosis

scholarly journals Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: A systematic review

2021 ◽  
Author(s):  
Lauren K. Dillard ◽  
Ricardo X. Martinez ◽  
Lucero Lopez Perez ◽  
Amanda M. Fullerton ◽  
Shelly Chadha ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hearing Loss ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Tuberculosis Patients ◽  
Resistant Tuberculosis

scholarly journals Ototoxicity of Non-aminoglycoside Antibiotics

2021 ◽  
Vol 12 ◽  
Author(s):  
Leonard P. Rybak ◽  
Vickram Ramkumar ◽  
Debashree Mukherjea
Keyword(s):  
Hearing Loss ◽  
Animal Studies ◽  
Developing Nations ◽  
Aminoglycoside Antibiotics ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Polypeptide Antibiotic

It is well-known that aminoglycoside antibiotics can cause significant hearing loss and vestibular deficits that have been described in animal studies and in clinical reports. The purpose of this review is to summarize relevant preclinical and clinical publications that discuss the ototoxicity of non-aminoglycoside antibiotics. The major classes of antibiotics other than aminoglycosides that have been associated with hearing loss in animal studies and in patients are discussed in this report. These antibiotics include: capreomycin, a polypeptide antibiotic that has been used to treat patients with drug-resistant tuberculosis, particularly in developing nations; the macrolides, including erythromycin, azithromycin and clarithromycin; and vancomycin. These antibiotics have been associated with ototoxicity, particularly in neonates. It is critical to be aware of the ototoxic potential of these antibiotics since so much attention has been given to the ototoxicity of aminoglycoside antibiotics in the literature.

scholarly journals Hearing loss among patients on treatment for drug-resistant tuberculosis in Uganda

2021 ◽  
Vol 14 (3) ◽  
pp. 80-84
Author(s):  
Lodiong Jackson Dumo Lodiong ◽  
Timbine Amos ◽  
Boniface Amanee Elias Lumori ◽  
Edwin Nuwagira
Keyword(s):  
Hearing Loss ◽  
Cox Model ◽  
Hearing Threshold ◽  
P Value ◽  
Drug Resistant ◽  
Treatment Unit ◽  
Drug Resistant Tuberculosis ◽  
Regional Referral Hospital ◽  
Resistant Tuberculosis ◽  
Male Sex

Introduction: Second-line injectable therapy using aminoglycosides (AG) like kanamycin, amikacin or capreomycin is associated with irreversible hearing loss. We aimed to determine the incidence and predictors of hearing loss among patients with drug resistant tuberculosis (DR-TB) who received AG.Method: This was a retrospective cohort study conducted at the tuberculosis treatment unit of Mbarara Regional Referral Hospital (MRRH). All adult patients with a diagnosis of DR-TB between March 2016 and December 2019 were candidates for inclusion in the study. Hearing loss was defined as a hearing threshold of >20 decibels (dB) at any test frequency in at least one ear. The incidence and predictors of hearing loss were analysed using multivariable Cox model. A p-value of ≤0.05 was considered as statistically significant. Data analysis was done using STATA version 13.Results: The estimated rate of developing hearing loss was 107 per 1000 person months. Thirty-seven (52.9%) of 70 DR-TB patients experienced some degree of hearing loss, of which 25 (67.6 %) developed mild, 5 (13.5%) moderate, and 3 (8.1%) severe hearing loss. Male sex (HR 2.05, CI 1.03-4.10, p-value 0.041), increasing age (HR.5.17, CI 1.42-18.87, p-value 0.013) and high BMI (HR 3.31, CI 1.15 - 9.53, p-value 0.026) were significant predictors of new onset of hearing loss.Conclusion: The incidence of hearing loss among DR-TB patients was high, with the majority having a mild hearing loss. Patients who were male, older, overweight and/or obese were more likely to develop AG-induced hearing loss.

scholarly journals Hearing thresholds in patients with drug-resistant tuberculosis: baseline audiogram configurations and associations

2017 ◽  
Vol 43 (3) ◽  
pp. 195-201 ◽  
Author(s):  
Olusola Ayodele Sogebi ◽  
Muse Olatunbosun Fadeyi ◽  
Bolanle Olufunlola Adefuye ◽  
Festus Olukayode Soyinka
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Pure Tone ◽  
Pure Tone Audiometry ◽  
Male Gender ◽  
Sensorineural Hearing ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Antituberculosis Treatment

ABSTRACT Objective: To use baseline audiogram parameters in order to ascertain whether drug-resistant tuberculosis (DR-TB) has effects on hearing, as well as to describe the configurations of the audiograms and to determine whether there are parameters that can be associated with those configurations. Methods: This was a prospective study involving patients diagnosed with DR-TB at a tuberculosis treatment center in the state of Ogun, in Nigeria. The patients included in the study were submitted to pure tone audiometry at baseline (within two weeks after treatment initiation). For comparative analyses, data regarding demographic and clinical characteristics were collected from the medical records of the patients. Results: The final sample comprised 132 patients. The mean age of the patients was 34.5 ± 12.6 years (range, 8-82 years), and the male:female ratio was 2:1. Of the 132 patients, 103 (78.0%) resided in neighboring states, 125 (94.7%) had previously experienced antituberculosis treatment failure, and 18 (13.6%) were retroviral-positive. Normal audiograms were found in 12 patients (9.1%), whereas sensorineural hearing loss was identified in 104 (78.8%), the two most common configurations being ascending, in 54 (40.9%), and sloping, in 26 (19.7%). Pure-tone averages at low frequencies (0.25-1.0 kHz) and high frequencies (2.0-8.0 kHz) were 33.0 dB and 40.0 dB, respectively. Regarding the degree of hearing loss in the better ear, 36 patients (27.3%) were classified as having normal hearing and 67 (50.8%) were classified as having mild hearing loss (26-40 dB), whereas 29 (21.9%) showed moderate or severe hearing loss. Among the variables studied (age, gender, retroviral status, previous treatment outcome, and weight at admission), only male gender was associated with audiometric configurations. Conclusions: In this sample of patients with DR-TB, most presented with bilateral, mild, suboptimal sensorineural hearing loss, and ascending/sloping audiometric configurations were associated with male gender.

scholarly journals Clinical Guidelines for Managing Hearing Loss as a Complication of Drug-Resistant Tuberculosis Treatment: An Evaluation of Implementation fidelity in Kano, Nigeria

2021 ◽  
Author(s):  
Sani Ibrahim Muhammad ◽  
Ejemai Amaize Eboreime ◽  
Vivian Ifeoma Ogbonna ◽  
Iliyasu Zubairu ◽  
Latifat Ibisomi
Keyword(s):  
Hearing Loss ◽  
Work Experience ◽  
Implementation Fidelity ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Management Guidelines ◽  
Tb Treatment ◽  
Resistant Tuberculosis ◽  
Quality Of Delivery

Abstract Background: Nigeria has a high burden of Tuberculosis (TB) including Drug-resistant Tuberculosis (DR-TB) and hearing lossObjective: To measure the implementation fidelity of management guidelines for hearing loss resulting from DR-TB treatment and to identify its determinants Method: A questionnaire-based cross-sectional study was conducted at the Infectious Disease Hospital, Kano. Implementation fidelity of the Programmatic Management guidelines for the treatment of Drug-resistant Tuberculosis was measured under the four domains of content, coverage, duration and frequency. The determinants examined are intervention complexity, facilitation strategies, quality of delivery and participant responsiveness as proposed by the Carroll et al framework. Other determinants used are age, sex, professional cadre and work experience of healthcare providers.Results: The Implementation fidelity score ranged from 40 - 64% with a mean of 47.6%. Quality of delivery, intervention complexity, participants’ responsiveness, and being a medical doctor exerted a positive effect on implementation fidelity while facilitation strategy, age and work experience exerted a negative effect on implementation fidelity. Conclusion: The implementation fidelity of management guidelines for hearing loss resulting from DR-TB treatment was low. Implementation fidelity should be assessed early and at intervals in the course of implementing the PMDT guideline and indeed, in the implementation of any intervention.

scholarly journals The Psychosocial Impact of Hearing Loss on the Quality of life in Adults with Multi-Drug Resistant Tuberculosis (Preprint)

2019 ◽  
Author(s):  
Amanda Thusi ◽  
Jessica Paken
Keyword(s):  
Quality Of Life ◽  
Health Care ◽  
Hearing Loss ◽  
Well Being ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Multi Drug Resistant Tuberculosis ◽  
Mdr Tb

BACKGROUND Aminoglycoside treatment used for MDR-TB is likely to result in ototoxicity. The effects of a hearing loss with a MDR-TB diagnosis are likely to have an increased impact on the overall quality of life of an individual. However, there is minimal research in the area, which would therefore indicate a possible lack of awareness to the effect of aminoglycoside treatment on the quality of life of patients. While most studies on drug resistant TB are focused on the public health concerns of the disease, the human costs of MDR-TB are sometimes overlooked. OBJECTIVE This study aims to describe the psychological, social, economic and vocational impact of hearing loss on the quality of life of adults with Multi-Drug Resistant Tuberculosis. METHODS A Qualitative Phenomenological research study will be conducted on 10 participants. All participants will have a laboratory confirmed diagnosis of Multi-Drug Resistant Tuberculosis. A semi-structured interview questionnaire will be used to collect data. Face-to-face interviews will be conducted and the participants will be audio recorded. All interviews will be conducted by the researcher. RESULTS The study has not concluded. CONCLUSIONS The quality of life of a patient needs to be considered in the health care system during treatment, as this data may drive improved national health care planning with regards to treatment of patients diagnosed with MDR-TB. Therefore, for a comprehensive assessment of patient’s health status, it is very much essential to assess the overall impact of MDR-TB on health and patient’s perception of well-being. Besides routine clinical and bacteriological assessments, this assessment can be done by assessing quality of life which has several domains. Patients diagnosed with MDR-TB who further acquire an aminoglycoside induced hearing loss may have life-long effects on their quality of life even after completion of treatment.

Sign in / Sign up

Export Citation Format

Share Document